Iconovo’s CEO interviewed by DNB Carnegie

Iconovo’s CEO Anders Månsson, was recently interviewed by DNB Carnegie to discuss the company’s latest quarterly report. In the interview, Anders shares his view on Iconovo’s ongoing transition from a platform-focused development company to a more business-driven organisation with increased focus on partnerships and commercial opportunities.

Anders highlights progress in key projects such as ICOres®, ICOpre®, and the inhaled semaglutide programme, as well as the company’s strategy to expand partnerships and strengthen its financial position. He also comments on the ongoing rights issue, with a subscription period running from 13–27 February.